Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Posts Q2 Revenue Rise, Widened Loss

SAN FRANCISCO, Aug. 5 - Ciphergen Biosystems today reported an increase in second-quarter revenue and a widened net loss.


For the three months ended June 30, Ciphergen reported total revenues of $8.7 million compared with $3.7 million for the same period one year ago. The company said the increase was due to inclusion of revenue from its BioSepra Process division, acquired in July 2001, and increased sales of its ProteinChip systems and arrays.


Net loss for the quarter increased to $7.3 million, or $.27 per share, compared to $5.8 million, or $.22 per share, for the year-ago period.


R&D spending rose to approximately $4.7 million compared to $3 million for the second quarter in 2001.


The company said it had roughly $63.7 million in cash, cash equivalents, and investments in securities as of June 30.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.